Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding the clinical phenotype of HIST1H1E syndrome: cerebellar atrophy and bilateral optic neuropathy, a case report.

Frontiers in neurology·2026
Same author

Early Alzheimer's disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries.

The journal of prevention of Alzheimer's disease·2025
Same author

Probability and Neurodegeneration: Alzheimer's Disease and Huntington's Disease.

Brain sciences·2025
Same author

Cannabis Use Moderates Methamphetamine- and HIV-Related Inflammation: Evidence from Human Plasma Markers.

Viruses·2025
Same author

Evaluating the Online Mood Assessment Post Stroke (O-MAPS) training: a phase II randomized-controlled trial.

Topics in stroke rehabilitation·2025
Same author

At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use.

The American journal of drug and alcohol abuse·2025

Related Experiment Video

Updated: Jul 13, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations.

Jeffrey M Rogers1, Peter K Panegyres

  • 1Neurosciences Unit, Health Department of Western Australia, Perth, Western Australia, Australia.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|July 31, 2007
PubMed
Summary

Cognitive impairment is frequent in multiple sclerosis (MS) and impacts quality of life. Recommended screening tests include the Symbol Digits Modalities Test and MS Neuropsychological Screening Questionnaire.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jul 13, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neurology
  • Neuropsychology

Background:

  • Cognitive impairment is prevalent in multiple sclerosis (MS) across all disease stages.
  • It significantly contributes to vocational disability, social challenges, and reduced quality of life.
  • Commonly affected cognitive domains include memory, information processing speed, working memory, and abstract reasoning.

Purpose of the Study:

  • To identify reliable screening tools for cognitive impairment in multiple sclerosis patients.
  • To inform clinical practice regarding the assessment of cognitive deficits in MS.

Main Methods:

  • Review of cognitive deficits commonly observed in MS.
  • Evaluation of established neuropsychological tests for their relevance in MS.
  • Consideration of clinical factors influencing cognitive function in MS.

Main Results:

  • Cognitive impairment in MS correlates with specific neuronal tissue damage, not strongly with disease duration or physical disability.
  • Factors like disease course, fatigue, mood disturbances, and medications can influence cognitive performance.
  • The Symbol Digits Modalities Test, Paced Auditory Serial Addition Task, Clock Drawing Test, and MS Neuropsychological Screening Questionnaire are proposed as valid screening instruments.

Conclusions:

  • Cognitive impairment is a significant and multifaceted issue in multiple sclerosis.
  • The suggested screening tests offer a practical approach to identifying cognitive deficits in MS patients.
  • Early and accurate screening can aid in managing the impact of cognitive impairment on patients' lives.